F. Olmo

A panel of phenotypically and genotypically diverse bioluminescent: fluorescent Trypanosoma cruzi strains as a resource for Chagas disease research

The paper describes a panel of bioluminescent and fluorescent Trypanosoma cruzi strains to study Chagas disease, enabling real-time monitoring of infection dynamics and drug screening.

Cryo-EM led analysis of open and closed conformations of Chagas vaccine candidate TcPOP and its antibody response characterisation

This study determines the 3D structures of TcPOP in open and closed conformations using cryo-EM and evaluates its immunogenicity through antibody responses in mice.

Trypanosoma cruzi persisters that survive benznidazole treatment in vitro and in vivo are in a transient non-proliferative state.

This study identifies benznidazole-treated Trypanosoma cruzi persisters as transient non-proliferative parasites, not localized to specific tissues, and suggests their survival may involve DNA damage response or pre-existing non-replicative states.

Local association of Trypanosoma cruzi chronic infection foci and enteric neuropathic lesions at the tissue micro-domain scale

The paper identifies chronic T. cruzi infection foci in the colon linked to enteric neuropathic lesions, suggesting chemotherapy could prevent chronic disease.

Trypanosoma cruzi amastigotes have a reduced replication rate during chronic stage infections

This study shows that Trypanosoma cruzi parasites replicate less during chronic infections compared to acute stages, but still involve regular cycles of replication and host cell lysis.

Intracellular DNA replication and differentiation of Trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infection

This study uses genetically modified parasites to show that T. cruzi replication and differentiation are asynchronous within host cells throughout infection.

Non-invasive monitoring of drug action: a new live in vitro assay design for Chagas' disease drug discovery

This paper introduces a live in vitro assay using eGFP-expressing Trypanosoma cruzi to monitor drug action over 6 days, revealing pharmacodynamic profiles of benznidazole and posaconazole.

Immunity conferred by drug-cured experimental Trypanosoma cruzi infections is long-lasting and cross-strain protective

This study shows that drug-cured Trypanosoma cruzi infections in mice provide long-lasting, cross-strain immunity against re-infection, outperforming recombinant vaccines.